According to Jules Schaeffer, Merck's executive director of basic research, he remembers talk among Merck executives about doing work on Alzheimer's nine years ago.
The Supreme Court laid out a balancing test of sorts: a basic need for executive confidentiality and candor, weighed against the public interests of congressional oversight, a criminal probe or prosecution.